Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

The combination treatment showed a higher response rate but no significant survival benefits.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

The combination of encorafenib and binimetinib caused few skin issues.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Sorafenib can cause a unique skin reaction.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Tadalafil and Finasteride may help treat aggressive melanoma.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

The drug combination was safe and showed promise in treating advanced tumors.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.